Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02012673
Other study ID # RECOIL-study
Secondary ID
Status Completed
Phase N/A
First received September 4, 2013
Last updated June 26, 2017
Start date January 2014
Est. completion date September 2016

Study information

Verified date June 2017
Source University Medical Center Groningen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Rationale:

The combined data from 3 studies outside the Unites States investigating the Lung Volume Reduction Coil system (RePneu LVRC) showed statistically significant improvements in pulmonary function, exercise capacity and quality of life at both 6-Months and 12-Months post treatment. 24 months post treatment the improved pulmonary function and exercise capacity are slightly decreasing. Retreating the patient with the LVR coil system in other parts of the lung could potentially lead to new improvements in lung function, dyspnea, exercise capacity and quality of life and may reduce the rate of decline.

Objective:

To investigate the safety and feasibility of re-treating patients with severe Chronic Obstructive Pulmonary Disease (COPD) with the RePneu LVRC system.


Description:

Rationale:

The combined data from 3 studies outside the Unites States investigating the Lung Volume Reduction Coil system (RePneu LVRC) showed statistically significant improvements in pulmonary function, exercise capacity and quality of life at both 6-Months and 12-Months post treatment. 24 months post treatment the improved pulmonary function and exercise capacity are slightly decreasing. Retreating the patient with the LVR coil system in other parts of the lung could potentially lead to new improvements in lung function, dyspnea, exercise capacity and quality of life and may reduce the rate of decline.

Objective:

To investigate the safety and feasibility of re-treating patients with severe Chronic Obstructive Pulmonary Disease (COPD) with the RePneu LVRC system.

Study design:

This study is a non randomized uncontrolled intervention.

Study population: Patients with severe emphysema who have previously been treated with the lung volume reduction coil system and significantly improved in lung function, exercise capacity or quality of life, 6 months after the treatment.

Intervention:

Patients will receive a lung volume reduction coil treatment by bronchoscopy.

Main study parameter:

The safety objective of this study is to identify the potential number and type of device-related and procedure-related adverse effects.

Secondary study parameters:

Lung function

- Change in RV, 6 months following treatment

- Change in RV/TLC ratio, 6 months following treatment

- Changes in FEV1 and FVC, 2 and 6 months following treatment

Quality of life

- Change in the SGRQ score, 2 and 6 months following treatment

- Change in the CCQ score, 2 and 6 months following treatment

Functional measures

- Change in the mMRC score, 2 and 6 months following treatment

- Change in the 6MWD, 2 and 6 months following treatment


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date September 2016
Est. primary completion date September 2016
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

1. Treated with the RePneu LVRC system > 24 months ago.

2. Six months after the first bilateral treatment with the RePneu LVRC system the patient had a significant improvement above the established minimal important difference (MID) of 6-minute walk distance (6MWD: 26 meter) or of forced expiratory volume in 1 second (FEV1: 100ml) or of St. Georges Respiratory Questionnaire total score (SGRQ: 4 points).

3. Subject has marked dyspnea scoring =2 on mMRC scale of 0-4.

4. Subject has stopped smoking for at least 6 months prior to entering the study.

5. Subject read, understood and signed the Informed Consent form.

6. Subject has completed a pulmonary rehabilitation program within 6 months prior to treatment and/or regularly performing maintenance respiratory rehabilitation if initial supervised therapy occurred more than 6 months prior to baseline testing.

7. Subject has received Influenza vaccinations consistent with local recommendations and/or policy.

Exclusion Criteria:

1. Subject has co-morbidities that may significantly reduce subject's ability to improve exercise capacity (e.g., severe arthritis, planned knee surgery) or baseline limitation on 6MWT is not due to dyspnea.

2. Subject has severe gas exchange abnormalities as defined by:

PaCO2 >8.0 kPa; PaO2 < 6.0 kPa (room air).

3. Subject has a history of recurrent clinically significant respiratory infections, defined as 3 hospitalizations for respiratory infection during the year prior to enrollment.

4. Subject has severe pulmonary hypertension defined by right ventricular systolic pressure >50 mm Hg via echocardiogram.

5. Subject has an inability to walk >140 meters in 6 minutes.

6. Subject has evidence of other severe disease (such as, but not limited to, lung cancer or renal failure), which in the judgment of the investigator may compromise survival of the subject for the duration of the study.

7. Subject is pregnant or lactating, or plans to become pregnant within the study timeframe.

8. Subject has an inability to tolerate bronchoscopy under moderate sedation or general anesthesia.

9. Subject has clinically significant bronchiectasis.

10. Subject has giant bullae >1/3 lung volume.

11. Subject has had previous LVR surgery, lung transplantation or lobectomy.

12. Subject has been involved in pulmonary drug or device studies within 30 days prior to this study.

13. Subject is taking >20 mg prednisone (or equivalent dose of a similar steroid) daily.

14. Subject requires high level chronic immunomodulatory therapy to treat a moderate to severe chronic inflammatory autoimmune disorder.

15. Subject is on an antiplatelet (such as Plavix) or anticoagulant therapy (such as heparin or Coumadin) which cannot be stopped for 7 days prior to procedure.

16. Subject has a sensitivity or allergy to Nickel.

17. Subject has a known sensitivity to drugs required to perform bronchoscopy.

18. Subject has any other disease, condition(s) or habit(s) that would interfere with completion of study and follow up assessments, would increase risks of bronchoscopy or assessments, or in the judgment of the investigator would potentially interfere.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Bronchoscopic lung volume reduction
Bronchoscopic lung volume reduction with the RePneu Lung Volume Reduction Coil system. The RePneu LVRC is an implantable device, delivered through a fiber-optic bronchoscope, designed specifically to treat patients suffering from emphysema. The Coil is intended to compress the most damaged parenchyma and tension the surrounding tissue, which increases elastic recoil, reduces hyperinflation and redirects air to healthier portions of the lung for more effective ventilation.

Locations

Country Name City State
Netherlands University Medical Center Groningen Groningen

Sponsors (1)

Lead Sponsor Collaborator
University Medical Center Groningen

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number and type of adverse effects as a measure of safety between baseline and 6 months follow up The safety objective of this study is to identify the potential number and type of device-related and procedure-related adverse effects. Baseline - 6 month follow up
Secondary Change from Baseline in Lung function at 2 months -Changes in FEV1 and FVC, 2 months following treatment Baseline vs 2 month follow up
Secondary Change from Baseline in Quality of life at 2 months Change in the SGRQ score, 2 months following treatment
Change in the CCQ score, 2 months following treatment
Baseline vs 2 month follow up
Secondary Change from Baseline in functional measures at 2 months Change in the mMRC score, 2 months following treatment
Change in the 6MWD, 2 months following treatment
Baseline vs 2 month follow up
Secondary Change from Baseline in Lung function at 6 months Change in RV, 6 months following treatment
Change in RV/TLC ratio, 6 months following treatment
Changes in FEV1 and FVC, 6 months following treatment
Baseline vs 6 month follow up
Secondary Change from Baseline in quality of life at 6 months Change in the SGRQ score, 6 months following treatment
Change in the CCQ score, 6 months following treatment
Baseline vs 6 month follow up
Secondary Change from Baseline in functional measures at 6 months Change in the mMRC score, 6 months following treatment
Change in the 6MWD, 6 months following treatment
Baseline vs 6 month follow up
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06000696 - Healthy at Home Pilot
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Completed NCT04105075 - COPD in Obese Patients
Recruiting NCT05825261 - Exploring Novel Biomarkers for Emphysema Detection
Active, not recruiting NCT04075331 - Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial Phase 2/Phase 3
Terminated NCT03640260 - Respiratory Regulation With Biofeedback in COPD N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
Withdrawn NCT04210050 - Sleep Ventilation for Patients With Advanced Hypercapnic COPD N/A
Terminated NCT03284203 - Feasibility of At-Home Handheld Spirometry N/A
Recruiting NCT06110403 - Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness Phase 1/Phase 2
Active, not recruiting NCT06040424 - Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Recruiting NCT04868357 - Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program N/A
Completed NCT01892566 - Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV N/A
Completed NCT04119856 - Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD N/A
Completed NCT04485741 - Strados System at Center of Excellence
Completed NCT03626519 - Effects of Menthol on Dyspnoea in COPD Patients N/A
Recruiting NCT04860375 - Multidisciplinary Management of Severe COPD N/A